Scandion Oncology reports positive topline phase IIA data from the corist part 3 trial.
Read more
Scandion Oncology
Overcoming cancer drug resistance
Navbar
About us
Executive Management
Board of Directors
Clinical Advisory Board
Research & Development
Pipeline
Clinical Development
Science
Cancer drug resistance
Technology Platform
SCO-101
News & Press
Press releases
Media
Image library
Video library
Investors
Share information
Financial calendar
Financial Reports
Annual reports
Interim reports
Presentations
Business development
Analyst Coverage
Prospectuses
Rights Issue 2022
Rights Issue 2020
Rights Issue 2019
Subscription Warrant (SCOL TO 1)
IPO 2018
Corporate governance
Events
General meetings
Contact
Career
Skip to content
Event
Q1 2023 Report
« All Events
This event has passed.
26 May, 2023
«
AGM
Q2 2023 Report
»
Webcast link
Add to calendar
Google Calendar
iCalendar
Outlook 365
Outlook Live
Details
Date:
26 May, 2023
Event Category:
Financial Events
